Altimmune Inc
NASDAQ:ALT

Watchlist Manager
Altimmune Inc Logo
Altimmune Inc
NASDAQ:ALT
Watchlist
Price: 5.07 USD -1.93% Market Closed
Market Cap: 390.4m USD

Altimmune Inc
Investor Relations

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 47 full-time employees. The company went IPO on 2005-10-06. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The firm has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. The company is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Show more
Loading

Earnings Calls

2024 Q4
Feb 4, 2025
Show Transcript
Show Presentation
Show Presentation
Previous
Next
AMD's Strong Revenue Growth Fueled by Data Center and Client Segments
2024 Q4
Feb 4, 2025

AMD reported record revenue of $25.8 billion in 2024, a 14% increase, driven by a 94% surge in Data Center revenues, contributing 50% to annual revenue. The fourth quarter alone saw a 24% revenue increase to $7.7 billion, fueled by strong performances in Data Center and Client sectors. Notably, the Data Center AI business achieved over $5 billion in revenues. Looking ahead, AMD expects first quarter 2025 revenue between $7.1 billion and $7.4 billion, up 30% year-over-year, and anticipates continued double-digit growth for the Data Center segment throughout the year.

Show Full Analysis

Management

Dr. Vipin K. Garg Ph.D.
President, CEO & Director
No Bio Available
Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS
Chief Medical Officer
No Bio Available
Mr. Raymond M. Jordt M.B.A.
Chief Business Officer
No Bio Available
Mr. Gregory L. Weaver CPA, M.B.A.
Chief Financial Officer
No Bio Available
Mr. Andrew Shutterly M.S.
Principal Financial & Accounting Officer and Corporate Controller
No Bio Available
Mr. Bertrand Georges Ph.D.
Chief Technology Officer
No Bio Available
Dr. M. Scot Roberts Ph.D.
Chief Scientific Officer
No Bio Available
Mr. Tony Blandin B.S.
Vice President of Quality & Compliance Management
No Bio Available

Contacts

Address
MARYLAND
Gaithersburg
910 Clopper Rd Ste 201S
Contacts
+12406541450.0
altimmune.com